30 November -0001 | News | By BioSpectrum Bureau
Wockhardt Q1FY14 Net Sales at Rs.1358 crore and PAT at Rs.324 crore
Wockhardt from its quarter end result filed it was clealry observed that Wockhardt increased its research spent significantly and the same is now at 7.2% at Rs. 98 crores and including capital expenditure is at 7.7% to sales for the quarter.
Wockhardt has as of now filed 4 new product applications with USFDA during the quarter. Capital expenditure of Rs. 68 crore was incurred during the quarter.
Business Highlights: